NCT07605247 Tirzepatide Endometrioid intraepithelial neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07605247 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07605247 is a hot trial to watch

Endometrioid intraepithelial neoplasia is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07605247 is notable because it evaluates Tirzepatide in a Phase 2 design sponsored by Rutgers State University of New Jersey. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

This study is looking for a better way to treat pre-cancer or early-stage cancer in the lining of the uterus in women who are also overweight. Everyone in the study will receive the standard treatment, a Progesterone IUD (LNG-IUD). This device is put in the uterus and releases hormones to help fight the disease. We will add a new medicine, Tirzepatide, for some people. Tirzepatide is a shot that helps with weight loss and overall health. You will be placed into one of two groups by chance (like flipping a coin): 1. Group 1: You get the Progesterone IUD PLUS the Tirzepatide shot. 2. Group 2: You get the Progesterone IUD ONLY (Standard Treatment). During the study, you will be asked to fill out surveys often. These questions ask about your daily life, how you feel about your health and weight, and any side effects you might have. This helps us understand how the treatments affect you. You will have small tissue samples (biopsies) taken fr

Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across Not reported in the indexed record shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes. (● Screening (day -30 to Week 0) ● 3 months (Visit 4, Week 12) ● 6 months (Visit 7, Week 24) ● 9 months (Visit 10, Week 36)) — Quality of life will be measured through PROMs at the time points listed below for explorative purposes.

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: Tirzepatide is indexed as Synthetic peptide, with target GIPR x GLP-1R, mechanism GIPR agonists, GLP-1R agonists, and global highest development status Approved.

Company & Deal Intelligence MCP profile: Rutgers State University of New Jersey is resolved to a normalized organization record in BERNALILLO COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07605247 provides a focused lens on Endometrioid intraepithelial neoplasia development. Its value will be determined by whether Tirzepatide can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.